TIDES USA 2024
May 14-17, 2024 | Boston, MA, USA, Hynes Convention Center
We are attending TIDES USA in Boston!
TIDES USA is the industry’s largest and most renowned event to accelerate oligonucleotide and peptide products therapeutics to market. With over 1,500 scientists, engineers, and executives in attendance, TIDES USA is the only event that has a full coverage of discovery, development, and manufacturing.
The 2024 TIDES USA program features 6 concurrent tracks covering the following 6 scientific themes including in-depth development strategies, trends, and technologies across the entire spectrum of oligonucleotides, peptides, mRNA, and genome editing.
- Oligonucleotide Chemistry, Manufacturing & Controls
- Oligonucleotide Discovery, Preclinical and Clinical
- Peptide Chemistry, Manufacturing & Controls
- Peptide Discovery, Preclinical and Clinical
- mRNA Therapeutics/Vaccines & Genome Editing
- Drug Delivery Innovations
Stop by Areterna Booth #727 to learn how Areterna, a Synthgene company, is fueling the next generation of raw materials and services to enable mRNA and oligo therapeutics.
Join us for an exciting presentation by May Guo, Chief Commercial Officer of Areterna, in which she will discuss cap analogs and NTPs.
Track: mRNA Technology and Applications
Speaker: May Guo, Chief Commercial Officer, Areterna LLC
Date: Conference Day 2. Thursday, May 16, 2024
Time: 9:30-10:00 AM EDT
Presentation Title:
Discovering New Cap Analogs and Their Performances in Difference mRNA Constructs
Abstract:
With mRNA gaining acceptance as a therapeutic modality, more cap analogs may be needed to tailor for different applications, for example, burst of protein expression for gene editing vs. persistent expression for protein replacement. We employ an AI-assisted discovery platform, from in-silico design to molecular docking to performance analysis, with a goal to delineate structure-activity relationship. The top cap analog candidates were tested in-vitro and in-vivo using model mRNA constructs such as firefly luciferase. Furthermore, the top cap analogs were used to make various mRNA vaccines (e.g. RV, VZV, HPV) and tested in mice. We discovered that different cap analogs performed differently depending on mRNA sequence. More work needs to be done to identify the cause for performance variability. Since the novel cap analogs are new to the market, various testing was conducted in mice and NHP to demonstrate their safety.
Raw Materials and Services to Enable mRNA and Oligo Therapeutics
Whether your focus is on manufacturing mRNA or pioneering groundbreaking mRNA therapeutics, we are here to support you. Our products are designed to elevate your research to new heights.
Upcoming Events
Catch us at BIO 2024 in San Diego from June 3 – 6. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with over 20,000 industry leaders from across the globe.